JP2021535106A5 - - Google Patents
Info
- Publication number
- JP2021535106A5 JP2021535106A5 JP2021509210A JP2021509210A JP2021535106A5 JP 2021535106 A5 JP2021535106 A5 JP 2021535106A5 JP 2021509210 A JP2021509210 A JP 2021509210A JP 2021509210 A JP2021509210 A JP 2021509210A JP 2021535106 A5 JP2021535106 A5 JP 2021535106A5
- Authority
- JP
- Japan
- Prior art keywords
- gaboxadol
- pharmaceutically acceptable
- acceptable salt
- patient
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862721013P | 2018-08-22 | 2018-08-22 | |
| US62/721,013 | 2018-08-22 | ||
| PCT/US2019/047673 WO2020041574A1 (en) | 2018-08-22 | 2019-08-22 | Use of gaboxadol in the treatment of gastrointestinal tract disorders and asthma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021535106A JP2021535106A (ja) | 2021-12-16 |
| JP2021535106A5 true JP2021535106A5 (enExample) | 2022-08-24 |
Family
ID=69591079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021509210A Withdrawn JP2021535106A (ja) | 2018-08-22 | 2019-08-22 | 消化管障害および喘息の処置におけるガボキサドールの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210177805A1 (enExample) |
| EP (1) | EP3823619A4 (enExample) |
| JP (1) | JP2021535106A (enExample) |
| KR (1) | KR20210049855A (enExample) |
| CN (1) | CN112888437A (enExample) |
| AU (1) | AU2019326539A1 (enExample) |
| CA (1) | CA3110218A1 (enExample) |
| IL (1) | IL280859A (enExample) |
| MX (1) | MX2021002113A (enExample) |
| WO (1) | WO2020041574A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021174024A1 (en) | 2020-02-28 | 2021-09-02 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
| CN115551514A (zh) * | 2020-03-25 | 2022-12-30 | 萨奇治疗股份有限公司 | 用于治疗呼吸系统病症的药物的用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0974351A3 (en) * | 1998-04-24 | 2000-12-13 | Jouveinal | Medicament for preventing and treating gastrointestinal damage |
| AU4307800A (en) * | 1999-04-30 | 2000-11-17 | Merab Lomia | New indication for use of antiepileptic agents and medicines |
| EP1863808A1 (en) * | 2005-03-18 | 2007-12-12 | Transform Pharmaceuticals, Inc. | Gaboxadol forms, compositions thereof, and related methods |
| US20070203216A1 (en) * | 2006-02-14 | 2007-08-30 | Bjarke Ebert | Method of treating inflammatory diseases |
| CN108024997A (zh) * | 2015-07-17 | 2018-05-11 | 奥维德医疗公司 | 用加波沙朵治疗发育障碍的方法 |
-
2019
- 2019-08-22 CN CN201980069028.1A patent/CN112888437A/zh active Pending
- 2019-08-22 EP EP19852671.7A patent/EP3823619A4/en not_active Withdrawn
- 2019-08-22 MX MX2021002113A patent/MX2021002113A/es unknown
- 2019-08-22 CA CA3110218A patent/CA3110218A1/en active Pending
- 2019-08-22 AU AU2019326539A patent/AU2019326539A1/en not_active Abandoned
- 2019-08-22 US US17/270,377 patent/US20210177805A1/en not_active Abandoned
- 2019-08-22 JP JP2021509210A patent/JP2021535106A/ja not_active Withdrawn
- 2019-08-22 KR KR1020217008438A patent/KR20210049855A/ko not_active Withdrawn
- 2019-08-22 WO PCT/US2019/047673 patent/WO2020041574A1/en not_active Ceased
-
2021
- 2021-02-14 IL IL280859A patent/IL280859A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9220696B2 (en) | Pharmaceutical combinations for treatment of specific cancers | |
| JP6145778B2 (ja) | 特発性炎症性筋疾患の予防又は治療剤 | |
| WO2018062134A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| KR102843222B1 (ko) | 마이크로조말 트리글리세라이드 전달 단백질 억제제의 섬유화 질환 치료 용도 | |
| CA3144374A1 (en) | Treatment comprising sglt inhibitors, e.g. sglt 1/2 inhibitors | |
| CN113893256A (zh) | 化合物或其可药用盐、二聚体或三聚体在制备治疗癌症的药物中的应用 | |
| US20220241386A1 (en) | Micronutrient combination to reduce blood pressure | |
| US20110118297A1 (en) | Tivozanib and Temsirolimus in Combination | |
| CN108904484A (zh) | 一种没食子酸乙酯的用途 | |
| CN112569220B (zh) | 四氢次大麻酚在制备用于治疗肺动脉高压药物中的应用及含有四氢次大麻酚的药物组合物 | |
| JP2024506041A (ja) | 潰瘍性大腸炎を予防、処置、または改善するためのアミセリモド | |
| US20210186950A1 (en) | Combinations comprising tropifexor and cenicriviroc | |
| JP2021535106A (ja) | 消化管障害および喘息の処置におけるガボキサドールの使用 | |
| CA2538202C (en) | Use of ciclesonide for the treatment of inflammatory bowel diseases | |
| US20240216384A1 (en) | Composition for preventing or treating metabolic diseases, containing tricyclo derivative compound | |
| US6545044B2 (en) | Compositions of matter containing L-glutamine and pyridoxal-alpha-ketoglutarate | |
| US7842702B2 (en) | Treatment for irritable bowel syndrome | |
| WO2021081081A1 (en) | Methods of treating, ameliorating, and/or preventing cancer using pyrvinium compositions | |
| Salvadori et al. | TARGETING UPPER EVEROLIMUS BLOOD LEVELS WITH VERY LOW-DOSE CYCLOSPORINE IS EFFECTIVE AND SAFE IN DE NOVO RENAL TRANSPLANTATION: 448 | |
| WO2003059355A1 (en) | Quinazolinone compounds in combined modalities for improved cancer treatment | |
| Del Castillo et al. | A PHASE II RANDOMIZED PHARMACOKINETIC (PK) STUDY OF TACROLIMUS (TAC)-EVEROLIMUS (EVL) COMBINATION FOR KIDNEY TRANSPLANTATION (KT): 449 | |
| CN1682715A (zh) | 一种抗缺氧药物组合物 | |
| DOSE | Stanford Health Care Aminoglycoside Dosing Guideline | |
| CN107441095A (zh) | 阿昔洛韦减轻伊立替康毒性的医药新用途 | |
| Iwabayashi et al. | 97 VALSARTAN ATTENUATES LP (A)-INDUCED SEVERE NEOINTIMAL HYPERPLASIA: POSSIBLE CONTRIBUTION OF INTEGRIN ALPHA V BETA3 IN VASCULAR SMOOTH MUSCLE CELL |